Seven prognostic factors associated with poor DMFS after ILRR among patients with breast cancer were identified: ILRR receptor status (ER-positive/PR-negative/HER2-negative tumor), shorter DFI (DFI shorter than 48 months), recurrence site (chest wall recurrence with or without regional node, and isolated regional node recurrence), non-resection of ILRR, nodal stage in the primary tumor (N2 or N3), CT for the primary tumor, and no ET for the ILRR. The gene discussed is ERBB2; the disease is breast cancer.